Antabio SAS raises €25 m in Series B financing

According to Antabio SAS, the financing will be used to support the clinical development of MEM-ANT3310 to proof-of-concept.

MEM-ANT3310 is a next generation antibacterial combination designed to provide a unique coverage of priority Gram-negative pathogens including OXA-carbapenem-resistant Acinetobacter baumannii (CRAB), KPC- and OXA- carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa (PA). MEM-ANT3310 combines the well-known carbapenem meropenem (MEM) with ANT3310, a breakthrough serine-beta-lactamase (SBL) inhibitor developed by Antabio. The Class A, Class C and Class D beta-lactamase blocker is currently being tested in Phase 1 trials to treat life-threatening infections due to drug-resistant Gram-negative pathogens, including Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP).

Antimicrobial resistance (AMR) is recognised as a top priority by the World Health Organization. It is estimated that 5-10% of hospital patients in US and Europe develop a hospital-acquired (nosocomial) infection. .

Antabio’s portfolio includes two further programs: ANT3273, a groundbreaking, novel class, novel mode of action inhalation treatment of Pseudomonas aeruginosa (PA) infections, particularly those affecting patients with chronic pulmonary diseases (such as Bronchiectasis, Cystic Fibrosis and COPD); and ANT2681, a novel and potent metallo beta-lactamase (MBL) inhibitor to be combined with meropenem for the treatment of MBL-producing carbapenem-resistant Enterobacterales (CRE), particularly New Delhi metallo-beta-lactamase (NDM) carrying strains.